xRead - September 2022

Wise et al.

Page 423

Author Manuscript Author Manuscript Author Manuscript Author Manuscript TABLE IX.D.6. Study

design Study groups Clinical endpoint Conclusion

ILIT is effective and safe; results in a marked reduction of seasonal allergic symptoms.

ILIT is effective and safe, with notably low adverse reactions.

ILIT is effective and safe.

ILIT produced immunological changes but no improvement in symptoms.

ILIT with MAT-Fel d 1 (Recombinant major cat dander

allergen fused to a modular antigen transporter) was safe and induced

allergen tolerance after 3 injections.

ILIT enhanced safety and efficacy of immunotherapy and reduced

treatment time from 3 years to 8 weeks.

Seasonal allergic symptoms by VAS, safety of injections, nasal symptom score following nasal provocation test, IgE and IgG4 levels, inflammatory cells, rescue medication use

Patient diary score of allergy and asthma symptoms and medication use, local and systemic symptoms score after injections

Seasonal allergic symptoms by VAS, SPT, validated rhinitis QOL questionnaire

Combined symptom and medication score, global seasonal assessment, RQLQ

Immunological parameters, systemic adverse effects, nasal provocation test, SPT, validated rhinitis QOL questionnaire

Seasonal allergic symptoms by VAS, adverse events, safety of injections, rescue medication use, SPT, grass specific IgE levels

1 Aluminum hydroxide adsorbed, depot birch-pollen or grass-pollen vaccine; 2 Placebo

1 Aluminum hydroxide-adsorbed grass pollen extract; 2 Placebo

1 Three intralymphatic inguinal injections of 1000 SQ U birch pollen or grass pollen; 2 Placebo

1 6 injections of 1000 SQ-U of depot grass pollen extract, minimal interval of 14 days; 1 MAT-Fel d 1;

2 Three injections of 1000 SQ-U followed by 3 placebo injections; 3 Six placebo injections 2 Placebo (saline in alum)

1 Three 0.1-mL injections with 1000 SQ-U of aluminum hydroxide-adsorbed grass pollen extract injected into lymph node at day 0 and after 4 and 8 weeks;

2 54 subcutaneous injections over 3 years (cumulative dose of 4,031,540 SQ-U)

Birch-pollen-induced or grass-pollen-induced AR (n = 36):

Adolescents, grass-pollen-induced AR (n = 15):

Birch-pollen/grass-pollen-induced AR (pilot n = 6; RCT n = 15): Grass pollen-induced AR (n = 45):

Cat-dander-induced AR (n = 20):

blinded

blinded

and RCT, blinded

blinded

blinded

Evidence for the use of intralymphatic immunotherapy in the treatment of allergic rhinitis Study Year LOE Hylander et al. 1719 2016 1b RCT, Patterson et al. 1720 2016 1b RCT, Hylander et al. 1718 2013 1b Pilot study Witten et al. 1721 2013 1b RCT, Senti et al. 1717 2012 1b RCT,

Senti et al. 1716 2008 2b RCT, open Grass pollen-induced AR (n = 165):

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.